14-536
MAP Kinase 2/Erk2 Protein, inactive, Human, 50 g
Unactive, N-terminal GST-tagged, recombinant human full length MAP Kinase 2, for use in Kinase Assays.
产品名称
MAP Kinase 2/Erk2 Protein, inactive, Human, 50 g, Unactive, N-terminal GST-tagged, recombinant human full length MAP Kinase 2, for use in Kinase Assays.
biological source
human
recombinant
expressed in E. coli
mol wt
Mw 67.8 kDa
manufacturer/tradename
Upstate®
technique(s)
activity assay: suitable (kinase)
NCBI accession no.
UniProt accession no.
shipped in
dry ice
Quality Level
Legal Information
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Analysis Note
routinely evaluated by phosphorylation of MBP substrate
Application
Research Category
Metabolism
Inflammation & Immunology
Metabolism
Inflammation & Immunology
Research Sub Category
Obesity
Metabolic Disorders
Osteoporosis
Arthritis
Obesity
Metabolic Disorders
Osteoporosis
Arthritis
Biochem/physiol Actions
Protein Target: MAPK2
Target Sub-Family: CMGC
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
General description
N-terminal GST-tagged, recombinant human full length MAP Kinase 2
Product Source: Expressed in E. coli
Other Notes
For Specific Activity data, refer to the Certificate of Analysis for individual lots of this enzyme.
Physical form
Glutathione agarose affinity chromatography
Preparation Note
6 months at -20°C
signalword
Warning
hcodes
Hazard Classifications
Skin Sens. 1
存储类别
12 - Non Combustible Liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Xiaoyun Wang et al.
Scientific reports, 6, 28260-28260 (2016-06-16)
Although the translational function of tRNA has long been established, extra translational functions of tRNA are still being discovered. We previously developed a computational method to systematically predict new tRNA-protein complexes and experimentally validated six candidate proteins, including the mitogen-activated
Ivana Yen et al.
Cancer cell, 34(4), 611-625 (2018-10-10)
Targeting KRAS mutant tumors through inhibition of individual downstream pathways has had limited clinical success. Here we report that RAF inhibitors exhibit little efficacy in KRAS mutant tumors. In combination drug screens, MEK and PI3K inhibitors synergized with pan-RAF inhibitors
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持